Qiagen holds annual general meeting of shareholders
QGEN•Qiagen shareholders authorized a capital repayment of up to $200 million and approved other share-related measures at the June 24, 2026 annual meeting. They also adopted the 2025 annual accounts and approved the dividend for 2026.
1. Shareholder approvals
Shareholders authorized a capital repayment of up to $200 million through a synthetic share repurchase that includes a reverse stock split and a reduction in ordinary shares’ par value to €0.01. They also authorized purchases of company shares and cancellation of company-held ordinary shares through December 24, 2027.
2. Other resolutions
The Supervisory Board received authorization through December 24, 2027, to issue ordinary shares and financing preference shares and restrict pre-emptive rights. Shareholders adopted the 2025 annual accounts and approved the dividend for 2026.
